A triple agonist of GLP-1, GIP and glucagon receptors (Table 1 and Table 3) was found to have better results in terms of reduction of body weight, improvement in glycemic control and reversion of hepatic steatosis in rodents in comparison with existing dual co-agonists and best-in-class mono-agonists [210]. Here, GLP1R is linked to fatty liver disease.